je.st
news
Tag: supplemental
EPA Issues Supplemental Funds to clean up Brownfields properties.
2015-09-28 14:31:10| Industrial Newsroom - All News for Today
U.S. EPA announced ~$13.2 million in supplemental funding to help communities by cleaning up contaminated Brownfields properties. Supplemental funding of Revolving Loan Funding (RLF) will be given to 31 RLF grantees and help 44 communities carry out cleanup and redevelopment projects. In addition to creating jobs, these projects will protect health of people and environment. Often, RLF funding provides last key piece needed to make property cleanup and reuse happen.
Tags: issues
properties
clean
funds
APPP Zone I Application & Supplemental Form for Businesses
2015-09-14 19:50:28| PortlandOnline
PDF Document, 111kbCategory: Permit Applications for Businesses
Tags: form
application
zone
businesses
APPP Zone I Application & Supplemental Form for Residents
2015-09-14 18:18:25| PortlandOnline
PDF Document, 41kbCategory: Permit Applications for Residents
Tags: form
application
zone
residents
Cotton Board Rules and Regulations Adjusts Supplemental Assessment on Imports
2015-09-02 10:00:00| Expeditors Newsflash - Americas Edition
Expeditors Newsflash - Americas Edition
Tags: board
rules
assessment
regulations
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] next »